SVCP
FLNA

Silicon Valley Capital Partners’s Filana Therapeutics FLNA Stock Holding History

Silicon Valley Capital Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96 Buy
+57
New +$117 ﹤0.01% 426

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Silicon Valley Capital Partners's FLNA Position: Q1 2026 in Review

Silicon Valley Capital Partners opened a new position in Filana Therapeutics (FLNA) in Q1 2026: 57 shares worth $96. The stake represents ﹤0.01% of the portfolio and ranks #426 among its holdings.

101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Silicon Valley Capital Partners held 57 shares of Filana Therapeutics worth $96 as of Q1 2026.
  • Filana Therapeutics was a new Silicon Valley Capital Partners position in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #426 holding.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.